In immune-competent individuals, human cytomegalovirus (HCMV) infection is associated with impairment of T-cell function. Our goal was to evaluate prospectively whether clinically asymptomatic HCMV infection in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients, treated pre emptively with ganciclovir, influences T-cell function as well. Mitogen-stimulated T-cell proliferative activity, together with cell surface markers, was tested in 49 patients on days þ 30, þ 45, þ 60, and þ 90 after alloHSCT and, additionally, in cases of positive HCMV pp65-antigenemia. HCMV infection was diagnosed in 19 patients. None of them developed HCMV disease. T-cell proliferative activity was significantly decreased on days when HCMV antigenemia was positive as compared to days without antigenemia. The number of pp65-positive cells negatively correlated with proliferative response. Comparison of patients who did experience HCMV infection with those who did not reveals significant decrease of T-cell proliferative activity observed on days þ 30 and þ 45, a time period when antigenemia was most frequently found to be positive, whereas no difference was detected on days þ 60 and þ 90. We conclude that, even clinically asymptomatic, HCMV infection has negative impact on T-cell proliferation capacity in alloHSCT recipients. However, pre emptive therapy with ganciclovir makes this immunosuppressive effect transient and restricted to the time of infection duration.
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Although the immune-suppressive effect of HCMV infection has been well documented for immune-competent individuals, so far it has not been tested prospectively in alloHSCT recipients. In a previously published retrospective study, Paulin et al 12 reported delayed immune reconstitution in patients given HSCT who experienced HCMV infection diagnosed either by serological methods or through virus isolation. In that study, the diagnostic tools, as well as the antiviral treatment, were, however, different from those currently used. 13 The goal of the present study was to prospectively evaluate the impact of HCMV infection, diagnosed through the use of the pp65-antigenemia assay, on post transplant immune recovery of allo-HSCT pediatric recipients, given ganciclovir therapy for HCMV infection on a pre emptive basis.
1,14

Patients and methods
Patients and donors
A total of 49 patients (30 males and 19 females), with a median age of 9.5 years (range 0.5-20.5) were included in the study. These patients received an allograft for either a malignant (n ¼ 30) or a nonmalignant (n ¼ 19) disease. Patients were transplanted from an HLA-identical sibling in 15 cases, from a single-haplotype compatible relative in 12, and from a matched unrelated volunteer (MUD) in the remaining 22 cases. The pre transplant HCMV serological status in the donor/recipient pairs was as follows: negative/ negative n ¼ 7, negative/positive n ¼ 17, positive/negative n ¼ 6, and positive/positive n ¼ 19. The median donor age was 35 (range 0.5-51) years (excluding three patients given a cord blood transplant).
HSCT procedure
Of the patients, 17 were treated with a preparative regimen based on the use of fractionated total body irradiation (TBI, 12 Gy over six fractions), whereas in 32 cases the conditioning regimen consisted of chemotherapy alone. The preparative regimen was myeloablative in all cases. Bone marrow was the source of stem cells in 33 patients, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood in 13 patients, and cord blood in three patients. All patients engrafted, the median time of neutrophil recovery (ie to reach an absolute neutrophil count 40.5 Â 10 9 /l) being 16 days (range 10-21). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) alone when the donor was an HLA-identical sibling, while the combination of CyA, short-term methotrexate (MTX) and pre-transplant antithymocyte globulin (ATG) were employed in patients transplanted from a MUD. Haploidentical HSCT recipients was given a T-cell-depleted graft containing less than 8 Â 10 4 T cells/kg in all cases; moreover, they were given ATG during the preparative regimen in order to reduce the risk of graft failure, without any further immunosuppression administered post transplantation. Nine patients developed grade II acute GVHD, while two children experienced grade III-IV acute GVHD. Steroids were used as a first-line therapy of acute GVHD; ATG or extracorporeal phototherapy was used as second-line treatment. 15 
HCMV monitoring and treatment
HCMV infection was defined as active HCMV replication in blood in the absence of clinical manifestations or organ function abnormalities, whereas HCMV disease required documentation of HCMV infection, together with clinical symptoms and/or organ function abnormalities. 16 HCMV infection was monitored with the use of antigenemia assay twice a week from day þ 14 post-HSCT, or earlier if the absolute neutrophil count exceeded 0.5 Â 10 9 /l, until day þ 100.
HCMV antigenemia was quantified by counting, at the fluorescence microscope, the number of pp65-positive peripheral blood leukocytes (PBL) on PBL cytospin preparations (each containing 2 Â 10 5 PBL) that were fixed and stained with a pool of pp65-specific monoclonal antibodies (mAb), according to a previously reported procedure. 17, 18 All patients were administered ganciclovir intravenously at a standard dosage of 5 mg/kg of body weight/b.i.d. until pp65 antigenemia clearance (ie, after two consecutive blood samples taken 2-3 days apart were negative for antigenemia). Ganciclovir therapy was started either immediately, when two or more pp65-positive PBL were detected, or when detection of one pp65-positive PBL was confirmed on the following 2-3 days by the same or a greater number of pp65-positive PBL. 14 
Sample collection
Heparinized peripheral blood samples (10 ml) were collected on days þ 30 (75), þ 45 (75), þ 60 (75), þ 90 (710), and, additionally, on the day when the pp65 antigenemia assay first was positive and 7 and 21 days from the start of ganciclovir treatment. The samples served for analysis of lymphocyte surface markers and evaluation of mitogen-stimulated T-cell proliferation.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) density gradient centrifugation, resuspended in RPMI 1640 medium (Gibco BRL, Life Technologies, Paisley, Scotland) supplemented with 2 mM L-glutamine and 50 mg/ml gentamicin (Gibco), 10% fetal calf serum (FCS; Euroclone-Celbio, Milano, Italy) (RPMI-FCS), and used on the same day or cryopreserved for later use.
Surface marker analysis
Lymphocyte subpopulations were assessed by immunophenotyping. The mAb used in this study included fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled anti-Leu-4 (CD3), anti-Leu-3a (CD4), anti-Leu-2a (CD8), anti-Leu-11c (CD16), anti-Leu-19 (CD56), antiLeu-7 (CD57), anti-Leu-1 (CD5), anti-Leu-12 (CD19), antiLeu-16 (CD20), anti-HLA-DR, and anti-Hle-1 (CD45) (BD Biosciences, Mountain View, CA, USA). Appropriate isotype-matched controls were included. Cell populations were identified on the basis of forward and side scatter analysis; CD45 mAb was used to exclude residual red blood cells. Data were calculated using CellQuest software (BD Biosciences).
Proliferation assay
T-cell proliferative activity was assessed by 3 HTdR incorporation after stimulation with mitogens. As T-cell mitogens, phytohemagglutinin (PHA-L; Boehringer, Mannheim, Germany), concanavalin A (ConA; Pharmacia, Uppsela, Sweden), and anti-CD3 (OKT3; Ortho, Raritan, NJ, USA) mAb were used. T-lymphocyte activation was 19 
Statistical methods
As distribution of the variables was different from normal (Kolmogorow-Smirnow test), data were expressed as median (range) and nonparametric statistics were used for statistical analysis.
Samples were divided into those collected at the time of antigenemia positivity and those collected on days when antigenemia assay resulted negative. The latter included samples from patients who experienced HCMV infection but collected on days when antigenemia was negative. The time post transplantation for both sets of samples was compared with the use of the Mann-Whitney U-test and did not differ (see Results). The Mann-Whitney U-test was used also to compare both subgroups for the results of proliferation assay (one for each tested mitogen) and for the absolute number of lymphocytes in each of the following subpopulations:
þ , and HLAÀDR þ were also expressed and analyzed as a percentage of CD3 þ cells. In order to exclude the influence of factors other than HCMV infection on the results of proliferation assay, the effect of donor type, source of stem cells, conditioning regimen, including the use of ATG, acute GVHD, concomitant steroid and ganciclovir therapy was tested in univariate analysis with the use of the Mann-Whitney U-test or the Kruskal-Wallis test, as appropriate. The variables with a P-value o0.05 were included in the logistic regression model together with HCMV antigenemia. Selection of significant factors was based on the forward stepwise procedure.
The results of the proliferation assay obtained on days of antigenemia positivity were correlated with the number of pp65-positive PBL with the use of R Spearman correlation. The impact of other transplant-related factors on viral load was tested with the use of the Mann-Whitney U-test or Kruskal-Wallis test, as appropriate.
In addition, both proliferation assay results and lymphocyte subpopulations were analyzed separately for patients who developed HCMV infection before day þ 100 and those without infection, and compared at the pre-selected time-points (day þ 30, þ 45, þ 60, þ 90) for the above patient subgroups using the Mann-Whitney U-test.
The impact of various clinical factors on the incidence of HCMV infection was tested with the use of Fisher's exact test.
Results
HCMV infection and sample collection
Positive HCMV pp65-antigenemia was detected in 19 (39%) patients. Median time of post transplant occurrence of HCMV infection was 37 days (range 13-65). The median initial number of pp65-positive PBL was two (range 1-16)/ 2 Â 10 5 PBL, whereas the median peak number of pp65-positive PBL reached during infection was five (range 1-65)/2 Â 10 5 PBL. Ganciclovir therapy was effective in all cases, resulting in pp65 antigenemia clearance. The median time from the first positive test to the first of two negative antigenemia tests was 17 days (range 5-40). None of the patients included in this study developed HCMV disease. Two patients died before day þ 90 because of acute GVHD.
The incidence of HCMV infection was 27, 50, and 33% in HLA-identical sibling, MUD, and haploidentical HSCT recipients, respectively (P ¼ 0.33). The frequency of HCMV infection with regard to the donor/recipient serological status was as follows: negative/negative 0%, negative/ positive 20%, positive/negative 20%, and positive/positive 63% (P ¼ 0.07). Out of the 11 patients (55%), six with grade II-IV acute GVHD had positivization of HCMV antigenemia (P ¼ 0.2). Median dose of methylprednisolone for patients with acute GVHD equaled 1 (0.3-2) mg/kg/day for those with concurrent HCMV infection and 0.5 (0.1-2) mg/kg for those who had HCMV antigenemia assay negative during the study period (P ¼ 0.76). None of the other factors, including age and sex, type of disease (malignant vs nonmalignant), type of conditioning (TBIvs chemotherapy-based), source of stem cells, and kind of immunosuppressive therapy, was found to influence the probability of HCMV antigenemia positivity.
A total of 198 peripheral blood samples were collected and analyzed. Of them, 30 samples were collected on days when antigenemia assay resulted positive and 168 samples were obtained concomitantly with antigenemia negative results (including those collected at least 7 days after clearance of HCMV infection). The two sample sets did not differ in terms of time interval elapsing from day of transplantation to day of collection (49 (28-94) vs 47 (13-99), respectively, P ¼ 0.84).
Proliferation assay
Proliferative activity of T cells in response to mitogen stimulation was significantly decreased in samples collected on days when antigenemia was positive as compared to those collected when antigenemia was negative for ConA (P ¼ 0.01). and OKT3 (P ¼ 0.01) and a tendency was observed for PHA (P ¼ 0.07) (see also Figure 1 ). Figure 2 illustrates the changes in results of the proliferation assay and the antigenemia assay from an individual patient who developed HCMV infection.
In univariate analysis, results of proliferation assay were negatively affected by the donor type (haploidentical vs HLA-identical sibling or unrelated; Po0.0001 for all mitogens), source of stem cells (peripheral blood vs bone marrow or cord blood; Po0.0001 for all mitogens), ATG as a part of preparative regimen (PHA, Po0.0001; ConA, P ¼ 0.001, OKT3, P ¼ 0.0002), concomitant steroid therapy (PHA, P ¼ 0.003; ConA, P ¼ 0.02; OKT3, P ¼ 0.02), and concomitant ganciclovir therapy (PHA, P ¼ 0.15; ConA, P ¼ 0.02; OKT3, P ¼ 0.02). Multivariate analysis revealed that T-cell proliferative response to mitogens was influenced independently by only two factors: haploidentical donor (ConA, odds ratio (OR) 8.7 (95% CI 3.7-20.7), Po0.0001; OKT3, OR 10.4 (95% CI 4.4-24.5), Po0.0001) and pp65 antigenemia (ConA, OR 3.5 (95% CI 1.3-8.9), P ¼ 0.01; OKT3, HR 3.0 (95% CI 1.2-7.6), P ¼ 0.02).
The proliferative activity correlated negatively with the number of pp65 þ PBL (OKT3, R ¼ À0.45, P ¼ 0.02; ConA, R ¼ À0.51, P ¼ 0.007; PHA, R ¼ À0.54, P ¼ 0.004) (see Figure 3 for details). The proliferation assay gave a particularly low result when more than five pp65 þ cells/ 2 Â 10 5 PBL were detected. A tendency was found for a higher number of pp65-positive PBL in haploidentical HSCT recipients compared to the remaining subgroups (2 (1-25) vs 1 (1-65) cells/2 Â 10 5 PBL, P ¼ 0.06), whereas other transplant-relapsed factors including occurrence of grade II-IV acute GVHD had no impact on viral load.
Comparison of patients who did develop HCMV infection with those who did not experience viral reactivation reveals that significant proliferation differences could be detected on days þ 30 and þ 45, while on days þ 60 and þ 90 results of the proliferation assay were similar for both patient subgroups. These findings were pronounced especially for OKT3 and ConA stimulation, whereas for PHA only a tendency was observed (Figure 4 ).
Lymphocyte subpopulations
Absolute numbers of lymphocyte-subpopulations
, obtained on days of pp65-antigenemia positivity and on days where antigenemia assay resulted negative, were not significantly different. However, for samples collected when pp65-antigenemia assay was positive, more CD3 þ cells expressed CD8 (64% (0-100%) vs 53% (0-100%), P ¼ 0.01) and HLAÀDR (65% (21-100%) vs 57% (1-100%), P ¼ 0.05). The percentage of HLAÀDR þ among CD3 þ cells correlated positively with the number of pp65 þ PBL (R Spearman ¼ 0.51, P ¼ 0.006), whereas the same correlation was not found for CD8 þ cells (R Spearman ¼ 0.19, P ¼ 0.34).
The comparison of lymphocyte subpopulations in pre-selected time-points after transplantation for patients who experienced HCMV infection and those who did not develop this complication did not reveal significant differences (data not shown).
Discussion
Although diagnosis and treatment of HCMV infection has improved during the last decades, HCMV-related disease still represents one of the major causes of morbidity and mortality in allo-HSCT recipients. 20 Since, once established, HCMV disease, in particular HCMV-related interstitial pneumonitis, is difficult to treat, it is essential to detect early HCMV infection, either as positive antigenemia, DNAemia, or mRNAemia, and to start antiviral therapy without delay. 14, 20, 21 Protection from HCMV disease is also dependent on the presence of virus-specific T lymphocytes that, in HSCT rcipients, are predominantly of donor origin. As demonstrated for adult patients given T-cell-depleted HSCT, 22 and recently confirmed in a setting of cord blood transplantation, the residual host-origin, T cells may also play a role in particular contexts. 23 In alloHSCT recipients, HCMV infection is mainly a consequence of latent-virus reactivation, in the absence of adequate immune control. Further progression may, Immunosuppresive effect of HCMV after alloHSCT S Giebel et al however, depend not only on patient-related factors, but also on virus-dependent immune evasion mechanisms. HCMV avoids immune response by interfering with the process of antigen recognition by T lymphocytes and NK cells. 3 On the other hand, the virus causes a state of T-cell hyporesponsiveness that is not restricted to the infection. Decrease of T-cell proliferative response to mitogens, as well as decreased ability to produce pro-inflammatory cytokines, was first described in immune-competent individuals with HCMV mononucleosis. 7, 8 The effect could be observed as soon as 6 h after exposure 24 and declined with convalescence. 7 Although experimental data suggested the role of a humoral factor produced by the virus, 24 this could not be identified for many years until the recent discovery by Kotenko et al 9 , who demonstrated that human HCMV encodes a homologue of IL-10. Despite only 27% identity with human IL-10, this virus-encoded protein has high affinity for human IL-10 receptor 1. 10 Furthermore, Spencer et al 11 demonstrated that the HCMV IL-10 homologue mediates a potent immunosuppressive stimulus, that is, decreases T-cell mitogen-stimulated proliferative activity, proinflammatory cytokine production, and HLA surface expression.
Although the HCMV-related immunosuppressive effect was well documented, both in vitro and in immunecompetent individuals with HCMV mononucleosis, its role in alloHSCT recipients remained unclear. In this study, we prospectively evaluated T-cell proliferative activity, as well as quantitative recovery of lymphocyte subpopulations, within the first 100 days after alloHSCT. These parameters were analyzed in the context of asymptomatic HCMV pp65-antigenemia and pre emptive treatment with ganciclovir. Despite the fact that, for a major part of samples, the corresponding number of pp65-positive cells was borderline for the diagnosis of HCMV infection (p2/ 2 Â 10 5 PBL), we were able to demonstrate decreased T-cell mitogen-stimulated proliferative activity in samples collected on days when pp65-antigenemia resulted positive, as compared to samples collected on days without pp65-antigenemia. As demonstrated in multivariate analyses the effect was independent from that of other factors, potentially associated with reduced T-cell proliferative activity. Strong negative correlation between results of the proliferation assay and the number of pp65 þ PBL further supports the hypothesis that it was the virus itself that affected T-cell function. Further efforts should be made to better elucidate the underlying mechanisms at the basis of the immune-suppressive effect played by HCMV. In this regard, attempts to block access to the IL-10 receptor of the IL-10 homologue could be of particular interest, as well as analysis aimed at exploring the potential role of CD4 þ / CD25 þ regulatory T cells.
AlloHSCT recipients, even after neutrophil recovery, remain at high risk of various viral and fungal infections. Impairment of T-cell function associated with HCMV infection may further increase this risk and have a potential clinical significance. In this regard, two recent reports have demonstrated that HCMV disease is associated with the subsequent development of invasive aspergillosis and that there is an increased risk for invasive aspergillosis among patients who developed HCMV infection (antigenemia) or disease. 25, 26 Thus, the relevance of asymptomatic HCMV pp65-antigenemia is probably wider than that associated with the risk of progression to life-threatening HCMV disease. Its effect on T-lymphocyte function, although not considered for the definition of disease, should be taken into account when planning the antiviral management strategy in alloHSCT recipients.
In our study group all patients received pre emptive ganciclovir as soon as the number of PBL positive for pp65 equaled 2/2 Â 10 5 cells in a single examination or 1/2 Â 10 5 cells confirmed on the next viral test. The parallel analysis of patients who experienced HCMV infection and those without pp65-antigenemia before day þ 100 after alloHSCT revealed that impairment of T-cell function was pronounced on days þ 30 and þ 45, whereas no differences could be observed on days þ 60 and þ 90. This finding indicates that the decrease of proliferative activity was restricted to the period when pp65-antigenemia was most frequently present and disappeared with resolution of HCMV infection/reactivation. Concomitant ganciclovir therapy when analyzed together with HCMV pp65 antigenemia was not found to impair independently T-cell function. In conclusion, our results strongly support the rationale for early pre emptive ganciclovir treatment, which is efficient not only for prevention of HCMV disease, but also enables rapid correction of virus-related impairment of immune competence.
